Legal Director, Intellectual Property

This role is considered Hybrid.OverviewThe Director, Patent Counsel will have a proven track record in managing complex patent portfolios and driving patent strategy aligned with business objectives. This position is hybrid and will be primarily located in Cambridge, MA.Key ResponsibilitiesManaging global patent portfolios relating to RNAi therapeutic agents and delivery technologies.Providing strategic IP counsel to internal stakeholders, including strategic guidance on patent portfolio development and management, licensing, and freedom-to-operate.Collaborating with R&D to identify and protect intellectual property.Providing legal advice on a variety of contracts, including sponsored research agreements, consulting agreements, and material transfer agreements, and the ability to collaborate effectively with research, business development, and legal teams.Managing lifecycle of patent portfolios for late stage clinical programs.Providing IP support for commercial products including filing of Orange Book listings, maximizing patent term extensions, and supporting regulatory filings worldwide.Building and maintaining strong relationships with external counsel.QualificationsMSc. in biology, chemistry or biochemistry required, Ph.D. preferred.Juris Doctorate from an accredited law school and a current member of good standing of at least one state bar and in good standing in all states where admitted.Admitted to practice before the United States Patent and Trademark Office.Minimum of 7 years of in-house or law firm experience in patent prosecution and lifecycle management.Proficiency in using scientific and IP databases.Excellent writing, analytical and communication skills.Strong interpersonal and collaboration skills.Organized, independent and detail-oriented.About Alnylam:

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.Our culture:

Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.

#J-18808-Ljbffr